Legal Status Overview
Gray AreaHawaii has no law, administrative rule, or Board of Pharmacy bulletin that names peptides, "research chemicals," or research-use-only compounds as a distinct legal category, so their status defaults to the general federal and state pharmacy framework. Under federal law, peptides like BPC-157 and TB-500 are unapproved drugs that cannot be marketed for human use, though FDA periodically decides whether they may be used as bulk ingredients by licensed compounding pharmacies. In Hawaii, any lawful peptide or compounded GLP-1 (semaglutide/tirzepatide) product must come from a state-licensed pharmacy or physician operating under Hawaii Revised Statutes Chapter 461 and Board of Pharmacy compounding rules that mirror federal 503A/503B standards. Selling peptides labeled "research use only" for human consumption, or buying them for personal self-injection outside a licensed medical/pharmacy relationship, falls into an unresolved gray zone that is not specifically addressed by Hawaii statute.
Key Points
- Hawaii has no statute or administrative rule that specifically names "peptides," "research chemicals," or research-use-only compounds as a distinct regulatory category; the Hawaii Board of Pharmacy's public rules, meeting minutes, and licensee announcements contain no peptide-specific bulletin. [5]
- Hawaii Revised Statutes Chapter 461 (Pharmacists and Pharmacy) defines and governs compounding, prescription drugs, and licensed pharmacy practice in Hawaii, and is the general state framework that would apply to any compounded peptide product. [6]
- Hawaii Administrative Rules section 16-95-110 requires Hawaii pharmacies to comply with USP compounding standards (USP 795 and 797), which is the state-level implementation of the same quality framework that underlies federal 503A compounding law. [7]
- Federal law under FDA Section 503A allows a licensed pharmacist or physician to compound a drug for an individual patient from a valid prescription using permitted bulk substances, and this is the only legal pathway for a Hawaii resident to obtain a compounded peptide product such as BPC-157 or a GLP-1 drug. [1]
- BPC-157 is classified by the FDA as an unapproved new drug that cannot lawfully be sold or marketed for human consumption anywhere in the United States, including Hawaii, regardless of whether it is labeled "research use only." [4]
- A Hawaii resident cannot legally buy or import peptides like BPC-157 or TB-500 for personal use without a valid prescription from a licensed Hawaii or telehealth-affiliated prescriber, since no FDA approval or Hawaii exemption permits over-the-counter or research-labeled sale for human self-administration. [10]
- Compounded semaglutide and tirzepatide became largely unavailable nationwide, including in Hawaii, after the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, ending the shortage-based exception that had allowed broad compounding of these GLP-1 drugs. [9]
- The Hawaii Uniform Controlled Substances Act (HRS Chapter 329) does not list BPC-157, TB-500, semaglutide, or tirzepatide as scheduled controlled substances, so enforcement against unlawful sale of these peptides in Hawaii would proceed under general unapproved-drug and pharmacy-licensing law rather than controlled-substance criminal penalties. [8]
Peptide-by-peptide status in Hawaii
| BPC-157 | BPC-157 is not FDA-approved and cannot be lawfully sold for human use in Hawaii, and its availability to Hawaii compounding pharmacies has fluctuated at the federal level, including an April 2026 FDA decision removing it from a restricted "Category 2" bulk-substances list that had barred compounding since September 2023. [3] |
|---|---|
| TB-500 | TB-500 (thymosin beta-4 fragment) is an unapproved research compound with no FDA-approved human use, meaning it cannot be legally marketed or sold for human consumption in Hawaii and was likewise subject to federal review of its compounding-bulk-substance status alongside BPC-157. [2] |
| Semaglutide / Tirzepatide (GLP-1 class) | Semaglutide and tirzepatide are FDA-approved prescription drugs (as Ozempic/Wegovy and Mounjaro/Zepbound) that can be legally obtained in Hawaii only by prescription, and broad compounded versions are no longer legally available there since the FDA declared the national drug shortages resolved in late 2024 and early 2025. [9] |
| HGH / Somatropin | Human growth hormone (somatropin) is a federally controlled prescription drug and can only be legally dispensed in Hawaii through a licensed prescriber for an FDA-approved indication, with no Hawaii-specific exception found for research-labeled HGH products. |
Sources
Last researched: 2026-09-09
Frequently asked questions
Can I buy peptides like BPC-157 in Hawaii without a prescription?
No -- buying BPC-157 or similar unapproved research peptides for human use in Hawaii without a prescription falls outside any lawful sales channel, because BPC-157 is an unapproved drug under federal law and Hawaii has no exemption allowing over-the-counter or research-labeled sale for self-administration. [4]
Is it legal to have peptides shipped to Hawaii for personal use?
Personal importation of unapproved research peptides into Hawaii for self-injection is a legal gray area not specifically addressed by Hawaii statute; federal law bars marketing these compounds for human use, so shipments intercepted or investigated could be treated as unlawful distribution of an unapproved drug.
Can a Hawaii telehealth doctor legally prescribe peptides or compounded semaglutide?
A Hawaii-licensed telehealth prescriber can only legally prescribe a compounded peptide or GLP-1 drug through a state-licensed 503A pharmacy under a valid patient-specific prescription, and broad compounded semaglutide/tirzepatide access ended once the FDA declared the national shortages resolved in late 2024 and early 2025. [9]
What happens if someone sells peptides illegally in Hawaii?
Because peptides like BPC-157 and TB-500 are not scheduled controlled substances under Hawaii's Uniform Controlled Substances Act, illegal sale would likely be pursued as an unapproved-drug or unlicensed-pharmacy-practice violation under Hawaii's pharmacy laws and federal FDA authority rather than as a controlled-substance narcotics offense. [8]
Does Hawaii have its own law banning research chemicals or peptides?
No -- Hawaii has no statute, administrative code section, or Board of Pharmacy bulletin that specifically names peptides or research chemicals as a distinct legal category, so their status in Hawaii is determined entirely by general federal drug law and Hawaii's ordinary pharmacy/compounding rules. [5]